Stock, pipeline and biotech catalyst intelligence
Reported statements
| USD | 2024 |
|---|---|
| Revenue | $6.2M |
| R&D expense | $14.3M |
| Operating income | −$32.9M |
| Net income | −$32.8M |
| Cash & equivalents | $1.0M |
| Total debt | $28.5M |
| Operating cash flow | −$26.0M |
| Free cash flow | −$26.9M |
Company profile
Scorpius Holdings, Inc., through its subsidiary Scorpius BioManufacturing, operates as an integrated contract development and manufacturing organization. The company engages in clinical and commercial drug substance manufacturing; and release and stability testing activities. It is also involved in the provision of various process development services, including upstream and downstream development and optimization, and analytical method development solutions, as well as cell line development, testing, and characterization services. The company serves the biotechnology and biopharmaceutical industries. The company was formerly known as NightHawk Biosciences, Inc. and changed its name to Scorpius Holdings, Inc. in February 2024. Scorpius Holdings, Inc. was incorporated in 2008 and is based in San Antonio, Texas.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.